Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care-Reference-Cited by-同舟云学术

Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care

Published:2023-10-25 Issue:1 Volume:103 Page:269-283
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Bostankolu Değirmenci Başak^ORCID,Yegin Zeynep Arzu^ORCID,Akdemir Ümit Özgür^ORCID,Dede Ali^ORCID,Gündem Gonca Gül^ORCID,Özkurt Zübeyde Nur^ORCID,Atay Lütfiye Özlem^ORCID,Yağcı Münci^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05511-z.pdf

Reference52 articles.

1. Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S (n.d.) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 2019;20(6):e302–e312. https://doi.org/10.1016/S1470-2045(19)30309-2

2. Sachpekidis C, Merz M, Raab MS, Bertsch U, Weru V, Kopp-Schneider A, Jauch A, Goldschmidt H, Dimitrakopoulou-Strauss A (2021) The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res 11(1):100. https://doi.org/10.1186/s13550-021-00846-y

3. Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ (2018) Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica 103(6):1047–1053. https://doi.org/10.3324/haematol.2017.177139

4. Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer B, Landgren O, Lightbody E, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O’Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner G, Valente N, Weiss BM, Zamagni E, Kumar SK (2021) Minimal residual disease in myeloma: application for clinical care and new drug registration. Clin Cancer Res 27(19):5195–212. https://doi.org/10.1158/1078-0432.CCR-21-1059

5. Zamagni E, Tacchetti P, Barbato S, Cavo M (2021) Role of imaging in the evaluation of minimal residual disease in multiple myeloma patients. J Clin Oncol 39(2):116–125. https://doi.org/10.1200/JCO.20.00386